Are there plans for further studies?
Other studies of danirixin as a treatment for COPD have been conducted and are
completed. There are no plans for any further studies of danirixin in COPD.
Where can I find more information about this study?
Clinical studies have unique study numbers that are included in publications and other
information about the study. The unique study numbers associated with this study are
shown below with internet links to scientific summaries and other information.
The scientific summaries include more details about the requirements for study
enrolment, the study visit schedule, results from other endpoints and more detailed
information about side effects.
Organisation Website Study Number
European Medicines
www.clinicaltrialsregister.eu 2016-003675-211
Agency
United States National
Institutes of Health www.clinicaltrials.gov NCT030349672
(NIH)
Your doctor can help you understand more about this study and the results. Speak to
your doctor about the treatment options available in your country. You should not
make changes to your care based on the results of this or any single study. Keep taking
your current treatment unless instructed by your doctor.
We would like to thank the patients who contributed to this study. The results of this
study will help answer scientific questions about treating patients with COPD.
The content for this document was finalised by GSK on the 22nd of August 2019. The
information in this summary does not include additional information available after this
date.
1https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003675-21
2https://clinicaltrials.gov/ct2/show/NCT03034967?term=205724&rank=1